2020
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A. Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal Of The American Academy Of Dermatology 2020, 84: 432-470. PMID: 32738429, DOI: 10.1016/j.jaad.2020.07.087.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisAAD-NPF GuidelinesRole of dermatologistsImportant clinical questionsAlternative medicine modalitiesUnited States populationTopical therapyPsoriasis managementTopical agentsMultisystem diseaseTreatment recommendationsClinical questionsAlternative medicinePsoriasisAvailable evidenceSeverity measuresCareTreatmentGuidelinesSeverity assessment methodsPatientsTherapyStates populationDermatologistsDisease
2012
Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know
Strober B, Armour K, Romiti R, Smith C, Tebbey P, Menter A, Leonardi C. Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. Journal Of The American Academy Of Dermatology 2012, 66: 317-322. PMID: 22243723, DOI: 10.1016/j.jaad.2011.08.034.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisOptimal therapy managementImmune-mediated disordersBiosimilar formPsoriasis populationAppropriate therapyTopical agentsTherapy managementBiosimilar agentsClinical relevanceGeneric therapiesPatient careTherapyPsoriasisImportant interventionDevelopment of biosimilarsPatientsBiosimilarsDermatologistsTreatmentBiopharmaceutical therapiesAgentsImportant differencesPrescribersRegulatory guidelines